Drugs / N-TEC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04633928 | Apr 2021 → Apr 2023 | — | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | N-TEC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04633928 ↗ |
| Action | Restore | “The engineered autologous nasal cartilage graft is used as a replacement for PDS or native cartilage in an interposition graft in the reconstruction of nasal septal perforations.” NCT04633928 ↗ |
| Route | Other | “Subsequently, the engineered cartilage is implanted into the defect of the nasal septum.” NCT04633928 ↗ |